Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of ASP2151 in Herpes Zoster Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~(1) Patients who have a rash associated with herpes zoster, and who can start receiving the study drug within 72 hours after onset of the rash~Exclusion Criteria:~1. Patients who are not expected to have an adequate response to oral antiviral medication~2. An extreme decline in immune function~3. Presence of serious complications~4. Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent:~   * AST or ALT ≥ 2.5 x upper limit of normal~  * Platelet count \< lower limit of normal~  * Serum creatinine ≥ 1.5 mg/dL~  * Creatinine clearance \< 50 mL/min~5. Current or previous history of malignant tumor within 5 years before informed consent~6. Diagnosis of autoimmune disease~7. Evidence of bone marrow suppression

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- ASP2151(200 mg) (Type: EXPERIMENTAL): once daily
- ASP2151(400mg) (Type: EXPERIMENTAL): once daily
- valaciclovir (Type: EXPERIMENTAL): 1000 mg three times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).